TURBT术后即刻灌注吡柔比星预防肌层浸润性膀胱癌复发的疗效及安全性观察

目的 评估TURBT术后即刻膀胱灌注吡柔比星对预防肌层浸润性膀胱癌复发的疗效及安全性.方法 回顾性分析我院于2013年1月至2019年6月收治的64例肌层浸润性膀胱癌病例资料.治疗模式均为TURBT+膀胱灌注.治疗组(n=26)术后24h内行膀胱灌注,对照组(n=38)术后24 ～48 h内行膀胱灌注.比较两组1、3、...

Efficacy and Safety of Immediate Pirarubicin Intravesical Instillation After TURBT in the Prevention of Recurrence of Muscle Invasive Bladder Cancer.

Objective To assess the clinical efficacy and safety of immediate pirarubicin intravesical instillation after transurethral resection of bladder tumor(TURBT)in the prevention of recurrence of muscle invasive bladder cancer(MIBC). Methods The clinical data of 64 patients with MIBC treated in our hospital from January 2013 to June 2019 were analyzed retrospectively, all patientsunderwent TURBT+ intravesical instillation, in whom there were 26 patients treated with pirarubicin intravesical instillation within 24h(treatment group)and 38 patients treated with pirarubicin intravesical instillation within 24~48 h(control group). The recurrence rate of 1-month,3-month,6-month,12-month after the treatment, the progress of tumor stage, the adverse reactions after intravesical instillation were compared between two groups. Results The 1-month recurrence rate(11.54%), 3-month recurrence rate(23.08%)and 6-month recurrence rate(38.46%)in treatment group were significantly lower than control group(44.74%, 63.16%, 65.79%), comparison has statistically significant(P<0.05);the 12-month recurrence rate between two groups(61.54% vs. 60.53%)has no statistically significant(P>0.05);there was no significant difference in tumor stage progression between two groups(23.08% vs. 31.58%, P>0.05);the incidence of fever(38.46%)and bladder irritation(42.31%)in treatment group is similar to control group(26.32%, 23.68%)with no significant difference(P>0.05);the incidence of hematuria in treatment group is significantly higher than control group(61.54% vs. 26.32%, P<0.05). Conclusion Immediate pirarubicin intravesical instillation after TURBT can reduce the early tumor recurrence rate and increase the benefits in those patients with MIBC, which will not increase the rate of tumor stage progression, worthy of clinical reference, but may increase the incidence of hematuria.